Clinical Trial Search

Primary: Percent Change From Baseline to Week 24 in Trunk Fat — -6.27; -8.36 percent change — p=0.177

Primary: Change From Baseline to Study Endpoint in Mean Weekly Pain Scores — -1.20; -1.82; -1.94 score on scale — p=0.0075

Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants

Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants

Primary: Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy — 3.3; 5.7 units on a scale

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: Number of Clinical Adverse Experiences (CAEs) Reported by Patients With up to 52 Weeks of Treatment — 31; 156; 1; 2 Participants

Primary: Hemoglobin A1C (A1C) at Week 18 — -0.73; -0.79; -0.22 Percent of glycosylated hemoglobin (A1C) — p=<=0.001

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.26; -0.48; -0.52; -0.58 Units on a Scale

Primary: Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value — 344; 7; 343; 123 subjects

Primary: Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) — 0; 0 percentage of participants

Primary: Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs) — 0; 0; 459; 234 Participants

Primary: Number of Hereditary Angioedema (HAE) Attacks Treated With C1INH-nf — 609; 598 attacks